COMPANIES The chief executive of Sanofi-Aventis has criticised the past dominance of science over commerce in the French pharmaceuticals group and the stifling of the companies it acquired, as he laid out a distinctive strategy almost one year into the job.
Chris Viehbacher told the Financial Times that further large-scale takeovers of the sort that had built the company were unlikely, and that he would keep smaller acquired companies at arms’ length to preserve their entrepreneurial spirit.
